iRadimed Corp. (NASDAQ:IRMD) – Equities research analysts at Roth Capital lowered their Q3 2016 EPS estimates for shares of iRadimed Corp. in a report issued on Wednesday. Roth Capital analyst C. Lewis now expects that the firm will post earnings per share of $0.09 for the quarter, down from their prior forecast of $0.19. Roth Capital currently has a “Neutral” rating and a $11.50 target price on the stock. Roth Capital also issued estimates for iRadimed Corp.’s Q4 2016 earnings at $0.04 EPS and FY2016 earnings at $0.51 EPS.
Separately, Zacks Investment Research cut iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 5th.
Shares of iRadimed Corp. (NASDAQ:IRMD) opened at 10.20 on Monday. iRadimed Corp. has a one year low of $9.76 and a one year high of $33.25. The company has a 50-day moving average price of $16.47 and a 200 day moving average price of $17.94. The stock has a market cap of $108.85 million, a price-to-earnings ratio of 14.66 and a beta of 1.28.
iRadimed Corp. (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, July 29th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.03. iRadimed Corp. had a return on equity of 30.52% and a net margin of 24.52%. The company earned $9.90 million during the quarter, compared to analyst estimates of $9.60 million. During the same quarter last year, the firm posted $0.16 EPS. The firm’s revenue for the quarter was up 30.3% on a year-over-year basis.
In related news, VP Steven M. Nardi sold 2,096 shares of the company’s stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $17.11, for a total value of $35,862.56. Following the sale, the vice president now directly owns 1,996 shares of the company’s stock, valued at $34,151.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 69.00% of the stock is owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC boosted its stake in iRadimed Corp. by 99.0% in the third quarter. Conestoga Capital Advisors LLC now owns 572,885 shares of the company’s stock worth $9,733,000 after buying an additional 285,050 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in iRadimed Corp. during the second quarter worth approximately $1,011,000. Ativo Capital Management LLC boosted its stake in iRadimed Corp. by 173.0% in the second quarter. Ativo Capital Management LLC now owns 57,347 shares of the company’s stock worth $1,248,000 after buying an additional 36,340 shares in the last quarter. Spark Investment Management LLC bought a new stake in iRadimed Corp. during the second quarter worth approximately $761,000. Finally, BlackRock Fund Advisors boosted its stake in iRadimed Corp. by 37.4% in the second quarter. BlackRock Fund Advisors now owns 105,283 shares of the company’s stock worth $2,291,000 after buying an additional 28,638 shares in the last quarter. 20.74% of the stock is currently owned by hedge funds and other institutional investors.
About iRadimed Corp.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for iRadimed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.